Cargando…
Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
OBJECTIVE: To assess the efficacy of golimumab (GLM) as a treatment option for juvenile idiopathic arthritis (JIA)-associated uveitis refractory to adalimumab (ADA). METHODS: Retrospective single-centre study including patients with JIA receiving GLM for active uveitis after failing ADA. JIA- and uv...
Autores principales: | Lanz, Sofia, Seidel, Gerald, Skrabl-Baumgartner, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380315/ https://www.ncbi.nlm.nih.gov/pubmed/34419092 http://dx.doi.org/10.1186/s12969-021-00630-1 |
Ejemplares similares
-
Golimumab for the treatment of refractory juvenile idiopathic arthritis-associated uveitis
por: William, Mridula, et al.
Publicado: (2012) -
Effectiveness of adalimumab in the treatment of juvenile idiopathic arthritis associated with uveitis
por: Zholobova, Elena, et al.
Publicado: (2014) -
Usefulness of Adalimumab in the Treatment of Refractory Uveitis Associated with Juvenile Idiopathic Arthritis
por: García-De-Vicuña, Carmen, et al.
Publicado: (2013) -
Adalimumab and severe uveitis in juvenile idiopathic arthritis (JIA) therapy
por: Alpigiani, MG, et al.
Publicado: (2008) -
Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
por: Kotaniemi, Kaisu, et al.
Publicado: (2011)